Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical safety or efficacy concerns were identified that impact approvability   Sobi to meet with FDA to discuss next steps for resubmission   Sobi® (STO: SOBI) today announced that the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Company’s Biologics License Application (BLA) for NASP (nanoencapsulated sirolimus plus pegadricase) for the treatment of adult patients with uncontrolled

Issue of Equity

26 June 2026   Ashoka WhiteOak Emerging Markets Trust plc   Issue of Equity   Ashoka WhiteOak Emerging Markets Trust plc (the ‘Company’) announces that it has issued 100,000 new ordinary shares of one penny each (the ‘Ordinary Shares’) pursuant to its block listing facility. The Ordinary Shares will be issued at a price of 188.3 pence per Ordinary Share, a premium to the prevailing net asset value per Ordinary Share.   Following the issue of Ordinary Shares, the Company's issued share capital will comprise 41,414,329 Ordinary Shares and this is the total number of

Photocure ASA: Annual general meeting held

Oslo, Norway, 26 June 2026: Photocure ASA (OSE: PHO), held its annual general meeting on 26 June 2026 at 17:00 hours (CEST). The minutes from the general meeting setting out the resolutions are attached hereto. For further information, please contact: Priyam Shah Vice President Investor Relations Tel: +17176815072 Email: priyam.shah@photocure.com Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for

Smoltek announces preliminary outcome of the rights issue of units, indicating that the issue is significantly oversubscribed

This press release is an English version of the previously published Swedish version, which has interpretive precedence. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE MEASURES OTHER THAN THOSE PROVIDED UNDER SWEDISH LAW.   Smoltek Nanotech Holding AB (publ) (“Smoltek” or the “Company”) today announces the preliminary

Metacon announces preliminary outcome of the rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT WOULD BE UNLAWFUL.  Metacon AB (publ) (“Metacon” or the “Company”) announces the preliminary outcome of the Company’s rights issue of up to 545,435,760 shares, which the Board of directors decided on 2 June 2026 (the “Rights Issue”). The subscription price in the Rights Issue was SEK 0.20 per share. The subscription period in the Rights Issue, which ended today on 26

Statement from the Board of Directors of Biosergen regarding the merger with Flerie

This statement is made by the Board of Directors of Biosergen AB (the "Company" or "Biosergen") pursuant to Section II.19 of the Swedish takeover rules for certain trading platforms (the "Takeover Rules"), due to the proposed merger between Biosergen and Flerie AB (”Flerie”). The Board of Directors of Biosergen (the "Board") has resolved to recommend the shareholders of Biosergen to vote in favour of the merger.Background The Boards of Directors of Biosergen and Flerie (together the "Companies") today jointly announced that the Board and the Board of Directors of Flerie have adopted a

The Board of Directors of Biosergen has resolved on a rights issue of shares of approximately SEK 40 million in connection with the merger with Flerie

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED. The Board of Directors of Biosergen AB (“Biosergen” or the “Company”) has today, on 26 June 2026, conditional upon the subsequent approval of the Extraordinary General Meeting, resolved on a rights issue of shares (the “Rights Issue”). The subscription price has been set at SEK 0.50 per share. The Company has

Resilience Investment Holdings Ltd Announces That It Has Received All Necessary Regulatory Approvals to Complete the Tender Offer for All Shares and Equity Securities in Tecnotree

Tecnotree Corporation Stock Exchange Release 26.6.2026 at 18.36 EESTNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THIS TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. Resilience Investment Holdings Ltd (“Offeror”) has, on February 5, 2026, commenced a voluntary recommended public cash tender offer for all the issued and outstanding shares (the “Shares” or, individually, a “Share”), all the issued fully paid compulsory

Flerie and Biosergen have agreed on a merger plan – Flerie’s first new investment since its listing on Nasdaq Stockholm

THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD ALSO NOT BE DISTRIBUTED IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES ANY OTHER DOCUMENTATION, REGISTRATION, OR MEASURES BEYOND WHAT IS GOVERNED BY SWEDISH LAW. Today, on 26 June 2026, Flerie AB (publ) (”Flerie”) and Biosergen AB (“Biosergen”) (together the ”Companies”) jointly announce that the Board of Directors of Flerie and the Board of Directors of Biosergen have

Biosergen Publishes 2025 Annual Report

June 26, 2026: Biosergen AB (“Biosergen” or the “Company”) hereby announces that the 2025 annual report is available on the company website www.biosergen.net   For further information about Biosergen, please contact:Tine Kold Olesen, CEO Telephone: +45 3135 5707E-mail: tine.olesen@biosergen.net Mark Beveridge, CFO Telephone: +46 76 805 8288E-mail: mark.beveridge@biosergen.net The Company's Certified Adviser is Carnegie Investment Bank AB (publ).

Norconsult awarded contract with AF Gruppen/Kystverket

Sandvika, 26 June 2026 (OSE: NORCO): Norconsult will lead the design and engineering group at the Stad Skipstunnel connection project, supporting contractor AF Gruppen in this milestone project for the Norwegian Coastal Administration (Kystverket).  The Stad ship tunnel will become the world's first full-scale ship tunnel. The tunnel will penetrate through the Stad Peninsula, connecting Moldefjorden and Kjødepollen in Western Norway. The ship tunnel will measure approximately 1.7 kilometres in length, 40 metres in width and 50 metres in height, and is designed to accommodate vessels up

Invesco Ltd: Form 8.3 - Prologis Inc; Public dealing disclosure

FORM 8.3 PUBLIC DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of Invesco Ltd. discloser:(b) Owner or   controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor

#26-231 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

#26-230 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

Inside information: Solwers has agreed on temporary waiver under its financing agreement

Solwers Plc, Company release, inside information, 26 June 2026 at 17:15 EEST Solwers Plc has negotiated with its main bank to resolve the situation concerning the net debt/EBITDA covenant included in its financing agreement. As a result of the negotiations, the bank has waived the review of the financial covenant terms on the 30 June 2026 testing date. The company will continue financing negotiations with its main bank.  On 17 June 2026, Solwers announced that it estimated that the company would not meet its current net debt/EBITDA covenant on the 30 June 2026 testing date, and that

Episurf Medical has entered into a financing agreement for the KlaraBo acquisition and closing of the property portfolio takes place on 2 July 2026

Episurf Medical AB (publ) (Nasdaq Stockholm: EPIS B) has entered into a financing agreement relating to the previously communicated acquisition of KlaraBo Empire Holding AB (“the KlaraBo Acquisition”). Closing of the property portfolio takes place on 2 July 2026. For one of the properties, legal closing will take place no later than 18 months after the closing date. “With the financing in place, we can proceed with the closing of the KlaraBo portfolio, which brings our completed property exposure to over SEK 1.5 billion. For one of the properties, legal closing will take place at a later

Transaction in Own Shares

Notification of Purchase of Own Shares Pursuant to the general authority given to the Company by its shareholders at its last annual general meeting on the 25 July 2025, the Company announces that, on 26 June 2026 it purchased a total of 105,000 of its own ordinary shares at a price of £1.001 per share from Rulegale Nominees Ltd.  The shares re-purchased, which constituted 0.2% of the then total issued ordinary share capital of the Company, have been cancelled. In accordance with Disclosure and Transparency Rule 5.6.1, following the purchase of own shares referred to above, there are

Hunter Group ASA – Notification of major shareholding – Proxies for EGM

Oslo, 26 June 2026 In connection with the extraordinary general meeting of Hunter Group ASA (the "Company") to be held on 29 June 2026 (the "EGM"), the chair of the Company's board of directors, Morten E. Astrup, or a person appointed by him, has received proxies without voting instructions to vote on behalf of 16,920,810 shares at the EGM, representing 12.55% of the shares and voting rights. Aggregated with Morten E. Astrup’s existing holding of 16,485,422 shares in the Company through Surfside Holding AS, the proxies result in combined voting rights exceeding the 20% threshold set out

There are no items matching the current filter
There are no more items matching the current filter
Back to top